Journals / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 4

Türk kronik myeloid lösemi çalışması: KML hastalarının geriye dönük kesitsel incelenmesi

Turkish chronic myeloid leukemia study: Retrospective sectional analysis of CML patients

Pages
351–358
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: here have been tremendous changes in treatment and follow-up of patients with chronic myeloid leukemia (CML) in the last decade.
📊
Key Findings & Data:Materials and Methods: In this article, we have evaluated 1133 patients results with CML in terms of demographical features, disease status, response, resistance and use of second-generation TKIs.
💡
Conclusion & Impact:Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: here have been tremendous changes in treatment and follow-up of patients with chronic myeloid leukemia (CML) in the last decade. Especially, regular publication and updating of NCCN and ELN guidelines have provided enermous rationale and base for close monitorization of patients with CML. But, it is stil needed to have registry results retrospectively to evaluate daily CML practices. Materials and Methods: In this article, we have evaluated 1133 patients results with CML in terms of demographical features, disease status, response, resistance and use of second-generation TKIs. Results: The response rate has been found relatively high in comparison with previously published articles, and we detected that there was a lack of appropriate and adequate molecular response assessment. Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care.

Özet

Amaç: Kronik myeloid lösemi (KML) tanısı olan hastalarda tedavi ve takip kriterleri son 10 yılda çok ciddi değişimlere uğramıştır. Özellikle NCCN ve ELN kılavuzlarının yayınlanması ve düzenli olarak güncellenmesiyle hastaların daha yakın takibi mümkün olmuştur. Ancak güncel uygulamaları değerlendirebilmek için kayıt ve retrospektif analizlere ihtiyaç vardır. Gereç ve Yöntemler: Bu çalışmada, ülkemizde 12 merkezin katılımıyla KML tanısıyla izlenen 1133 hastanın demografik özellikleri, hastalık durumları, yanıt, direnç ve ikinci kuşak tirozin kinaz inhibitör kullanımları analiz edilmiştir. Bulgular: Hasta grubumuzda, yanıt oranlarının litaretüre göre daha yüksek olduğu, moleküler yanıt değerlendirmenin tüm merkezlerde mümkün olmadığı saptanmıştır. Sonuç: KML hastalarının bakım kalitesinin arttırılması için moleküler teknik kullanımının arttırılması ve daha yaygın kayıt sistemine ihtiyaç vardır.

🔖

Cite This Article

ŞAHİN, F., SAYDAM, G., CÖMERT, M., UZ, B., YAVUZ, A. S., TURAN, E., HİNDİLERDEN, İ. Y., ATAY, M. H., KELTİKLİ, E., TURGUT, M., PEHLİVAN, M., AKAY, O. M., GÜRKAN, E., PAYDAŞ, S., KAHRAMAN, S., DEMİRKAN, F., KIRKIZLAR, O., AKPINAR, S., PAMUK, G. E., DEMİR, A. M. (2013). Türk kronik myeloid lösemi çalışması: KML hastalarının geriye dönük kesitsel incelenmesi. Turkish Journal of Hematology, Cilt: 30 - Sayı: 4, 351–358. https://ajindex.com/articles/412630

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L. Changes in the dynamic of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990- 2007: a population study. Blood 2011
  2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990
  3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990
  4. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973
  5. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988
  6. Kurzrock G, Gutterman J, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988
  7. Saydam G, Haznedaroglu IC, Temiz Y, Soysal T, Sucak G, Tombuloglu M, Ozdogu H, Yavuz S, Altintas A, Ozet G, Gulbas Z, Ferhanoglu B, Ilhan O. Retrospective evaluation of patients treated with dasatinib for Philadelphia positive leukemias: Turkish experience of 16 months. UHOD 2009
  8. O’Brien SG, Guilhot F Larson RA, Gathmann I, Baccarani M, Cervantes F Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ
  9. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003
  10. Druker BJ, Guilhot F O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA
  11. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006
  12. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O’Brien S, So C, Massimini G, Guilhot F Survival advantage from imatinib compared with combination interf